论文部分内容阅读
目的观察恩替卡韦(ETV)联合扶正化瘀胶囊治疗慢性乙型肝炎临床疗效。方法将慢性乙型肝炎患者70例随机分为ETV联合扶正化瘀胶囊治疗组及单用ETV对照组,各35例。观察两组治疗前、后肝功能、乙肝病毒DNA定量、肝脾彩超(门静脉主干直径及脾脏厚度)以及肝纤维化指标,包括血透明质酸(HA)、血层粘连蛋白(LN)、血Ⅱ型前胶原肽(PC-Ⅲ)。结果治疗后两组肝功能、乙肝病毒DNA、肝纤维化指标及肝脾彩超结果均较治疗前有好转,在肝纤维化指标及肝脾彩超变化上治疗组改善更显著,有统计学差异(P<0.05)。结论 ETV联合扶正化瘀胶囊通过抗病毒、抗纤维化为慢性乙型肝炎患者带来更好的疗效及预后。
Objective To observe the clinical efficacy of entecavir (ETV) combined with Fuzhenghuayu capsule in the treatment of chronic hepatitis B patients. Methods Seventy patients with chronic hepatitis B were randomly divided into ETV combined with Fuzhenghuayu capsule treatment group and ETV control group with 35 cases in each. The liver function, HBV DNA quantification, hepatopancreas and splenomegaly (portal vein diameter and spleen thickness) and hepatic fibrosis indexes including blood hyaluronic acid (HA), laminin (LN), blood Type II procollagen peptide (PC-III). Results After treatment, the liver function, hepatitis B virus DNA, indexes of liver fibrosis and the results of liver and splenic color of the two groups were better than those before treatment, and there was significant difference between the treatment group and the index of liver fibrosis P <0.05). Conclusion ETV combined with Fuzhenghuayu Capsule can bring better curative effect and prognosis to patients with chronic hepatitis B through antivirus and anti-fibrosis.